|Mr. Claude LeDuc||Pres, CEO & Director||N/A||N/A||1956|
|Mr. Luc Mainville M.B.A., M.B.A||Sr. VP & CFO||N/A||N/A||1964|
|Prof. Michael Buschmann||Chief Scientific Officer & Director||N/A||N/A||1962|
|Frederic Dumais||Director of Communications & Investor Relations||N/A||N/A||N/A|
|Mr. Guy Paul Allard||VP of Legal Affairs & Corp. Sec.||N/A||N/A||N/A|
Ortho Regenerative Technologies Inc., an orthopaedic and sports medicine biologics company, engages in the research and development of novel therapeutic tissue repair devices to enhance the success rate of sports medicine surgeries in Canada. The company develops Ortho-R, a formulation for rotator cuff repair; and Ortho-M, a biopolymer for bioactive meniscus repair. It also develops Ortho-C, a biopolymer for articular cartilage repair; and Ortho-V, a biopolymer for osteoarthritis healing. The company was incorporated in 2015 and is headquartered in Kirkland, Canada.
Ortho Regenerative Technologies Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.